Table 7

Prescription of the type of chemotherapy based on pathological stage and biology
Stage CMF-like Anthracyclines Anthracyclines + Taxanes Taxanes
Luminal A
IA* 3 (25.0%) 8 (66.7%) 0 (0%) 1 (8.3%)
IB** 16 (27.1%) 36 (61.0%) 7 (11.9%) 0 (0%)
II*** 16 (7.5%) 113 (53.1%) 75 (35.2%) 9 (4.2%)
III**** 5 (7.4%) 12 (17.6%) 47 (69.1%) 4 (5.9%)
Total 40 (11.4%) 169 (48.0%) 129 (36.6%) 14 (4.0%)
Luminal B
A* 1 (10.0%) 9 (66.7%) 0 (0%) 0 (0%)
IB** 7 (15.9%) 31 (61.0%) 7 (11.4%) 1 (2.3%)
II*** 10 (7.7%) 67 (53.1%) 44 (33.8%) 9 (6.9%)
III**** 0 (0%) 9 (17.6%) 36 (78.3%) 1 (2.2%)
Total 18 (7.8%) 116 (50.4%) 85 (37.0%) 11 (4.8%)
HER2
IA* 0 (0%) 22 (88.0%) 2 (8.0%) 1 (4.0%)
IB** 4 (5.2%) 54 (70.1%) 18 (23.4%) 1 (1.3%)
II*** 4 (3.3%) 55 (45.1%) 61 (50.0%) 2 (1.6%)
III**** 3 (6.7%) 6 (13.3%) 36 (80.0%) 0 (0%)
Total 11 (4.1%) 137 (50.9%) 117 (43.5%) 4 (1.5%)
Triple negative
IA* 4 (23.5%) 8 (47.1%) 4 (23.5%) 1 (5.9%)
IB** 8 (14.3%) 30 (53.6%) 14 (25.0%) 4 (7.1%)
II*** 3 (4.0%) 38 (50.7%) 32 (42.7%) 2 (2.7%)
III**** 2 (15.4%) 0 (0%) 9 (69.2%) 2 (15.4%)
Total 17 (10.6%) 76 (47.2%) 59 (36.6%) 9 (5.6%)

Clavarezza et al.

Clavarezza et al. BMC Cancer 2012 12:216   doi:10.1186/1471-2407-12-216

Open Data